MARK LYSIAK: Open Payments
NPI 1770284317 · ROCHESTER, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,629 in 69 payments from 32 companies in 2025. Trend: 2023 $3,135 · 2024 $3,577 · 2025 $1,629
Food & beverage: $1,529Education: $100
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 8 | $179 |
| Incyte Corporation | 3 | $145 |
| E.R. Squibb & Sons, L.L.C. | 7 | $135 |
| ABBVIE INC. | 6 | $116 |
| Janssen Biotech, Inc. | 2 | $95 |
| PFIZER INC. | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| Genentech USA, Inc. | 3 | $56 |
| Adaptive Biotechnologies Corporation | 2 | $56 |
| Merck Sharp & Dohme LLC | 2 | $55 |
Products named: OPDIVO, KISQALI, RYBREVANT, clonoSEQ, KEYTRUDA, XPOVIO, Enhertu, SCEMBLIX.
Industry payments across NY — which companies pay providers there.
